Loading...
XSHG
600161
Market cap4.78bUSD
Dec 05, Last price  
17.10CNY
1D
0.59%
1Q
-13.68%
Jan 2017
-26.64%
Name

Beijing Tiantan Biological Products Corp Ltd

Chart & Performance

D1W1MN
XSHG:600161 chart
P/E
21.83
P/S
5.61
EPS
0.78
Div Yield, %
0.88%
Shrs. gr., 5y
5.70%
Rev. gr., 5y
12.94%
Revenues
6.03b
+16.44%
343,358,631413,781,166530,504,687682,700,4311,100,252,9751,202,261,4091,394,395,3411,502,351,1601,836,504,0831,826,551,1271,617,985,9812,095,734,3011,765,169,6792,931,058,7283,281,859,5603,445,594,8654,112,155,6214,261,304,6225,180,441,7996,031,865,460
Net income
1.55b
+39.58%
68,999,532101,045,654104,702,668133,381,727211,659,754174,924,348233,349,955304,911,661372,028,783128,391,6739,977,207261,777,4411,179,942,696509,479,066894,253,782943,076,5911,068,813,8181,204,834,6911,109,888,5971,549,164,832
CFO
820m
-65.75%
131,685,718154,361,978153,548,280276,390,256448,226,847184,854,393353,150,675432,004,890566,433,984477,952,523473,258,905428,374,721218,389,433677,916,885642,468,858702,109,603980,350,1951,126,002,1902,393,576,031819,780,705
Dividend
Jun 20, 20240.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.
IPO date
Jun 16, 1998
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT